Stoke Therapeutics’ (STOK) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $35.00 price target on the stock.

A number of other research firms have also recently issued reports on STOK. Leerink Partners began coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Chardan Capital began coverage on Stoke Therapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $24.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $8.96 on Wednesday. The stock has a market cap of $474.58 million, a PE ratio of -4.27 and a beta of 0.95. The business has a fifty day moving average of $12.05 and a two-hundred day moving average of $13.11. Stoke Therapeutics has a 52-week low of $4.09 and a 52-week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Analysts predict that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 2,586 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $33,592.14. Following the completion of the transaction, the insider now directly owns 44,746 shares in the company, valued at approximately $581,250.54. The trade was a 5.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the transaction, the chief executive officer now owns 68,671 shares of the company’s stock, valued at $877,615.38. The trade was a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its holdings in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares in the last quarter. Quest Partners LLC bought a new position in Stoke Therapeutics in the second quarter valued at approximately $29,000. Los Angeles Capital Management LLC grew its stake in Stoke Therapeutics by 7.2% in the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after purchasing an additional 4,508 shares in the last quarter. Rhumbline Advisers grew its stake in Stoke Therapeutics by 14.3% in the second quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock valued at $647,000 after purchasing an additional 5,990 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in Stoke Therapeutics in the third quarter valued at approximately $160,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.